FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Guidance on ANDAs and Justification of Impurity Limits

[ Price : $8.95]

Federal Register Notice: FDA is making available a draft guidance for industry entitled ANDA Submissions Refuse to Receive for La...

Panel to Discuss Daiichi Sankyo NDA for Preventing Stroke/Embolism

[ Price : $8.95]

Federal Register Notice: FDAs Cardiovascular and Renal Drugs Advisory Committee will meet 10/30 to discuss a Daiichi Sankyo NDA fo...

Public Workshop Scheduled on E-Cigarettes

[ Price : $8.95]

Federal Register Notice: FDAs Center for Tobacco Products will hold a public workshop 12/10-11 to discuss electronic cigarettes.

Soligenix, FDA Reach Agreement on Lymphoma Trial

[ Price : $8.95]

Soligenix reaches an agreement with FDA on the design of a Phase 3 clinical trial of its synthetic hypericin product for treating ...

FDA Extends Review of Impax Parkinsons Drug

[ Price : $8.95]

FDA extends by three months its review of an Impax Pharmaceuticals NDA resubmission for Rytary (carbidopa and levodopa), an invest...

Court Protects Drug Company Report Contents

[ Price : $8.95]

The Drug and Device Law Blog praises a recent federal court decision protecting some company corporate integrity agreement documen...

Tryptase Test System Special Controls Guidance

[ Price : $8.95]

FDA issues a special controls guideline to support classification of a tryptase test system into Class 2 (special controls).

Defending Failure to Instruct/Train Claims

[ Price : $8.95]

Attorneys John Lavelle and Jacqueline Gorbey say medical device companies should ensure that they provide technical support reques...

Guidance on ANDA Refuse-to-Receive Standards

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance: ANDA Submissions Refuse-to-Receive Standards.

Advisors Recommend New Testosterone Labeling

[ Price : $8.95]

FDA advisory committee members call for new language in testosterone labeling.